BACKGROUND AND PURPOSE: To test whether changes in plasma tissue factor pathway inhibitor (TFPI) levels or activated protein C resistance (normalized activated protein C resistance ratio [nAPCsr]) modify the increased risk of ischemic stroke due to postmenopausal hormone therapy. METHODS: Nested case-control study of 455 cases of ischemic stroke and 565 matched control subjects in the Women's Health Initiative trials of postmenopausal hormone therapy. RESULTS: Baseline free TFPI was associated with ischemic stroke risk (OR per SD increase, 1.17; 95% CI, 1.01-1.37; P=0.039), but baseline nAPCsr was not (OR per SD increase, 0.89; 95% CI, 0.75-1.05; P=0.15). Baseline TFPI levels and nAPCsr did not modify the effect of postmenopausal hormone therapy on ischemic stroke. Treatment-induced mean changes of -28% in free TFPI and +65% in nAPCsr did not change the risk of ischemic stroke (interaction P=0.452 and 0.971, respectively). In subgroup analyses, baseline nAPCsr was inversely associated with lacunar strokes (OR per SD increase, 0.74; 95% CI, 0.57-0.96; P=0.025) and baseline free TFPI interacted with treatment to increase large vessel atherosclerotic strokes (P=0.008). CONCLUSIONS: Procoagulant changes in TFPI or nAPCsr do not modify the increased ischemic stroke risk due to postmenopausal hormone therapy. Clinical Trial Registration- URL: www.clinicaltrials.gov. Unique identifier: NCT 00000611.
RCT Entities:
BACKGROUND AND PURPOSE: To test whether changes in plasma tissue factor pathway inhibitor (TFPI) levels or activated protein C resistance (normalized activated protein C resistance ratio [nAPCsr]) modify the increased risk of ischemic stroke due to postmenopausal hormone therapy. METHODS: Nested case-control study of 455 cases of ischemic stroke and 565 matched control subjects in the Women's Health Initiative trials of postmenopausal hormone therapy. RESULTS: Baseline free TFPI was associated with ischemic stroke risk (OR per SD increase, 1.17; 95% CI, 1.01-1.37; P=0.039), but baseline nAPCsr was not (OR per SD increase, 0.89; 95% CI, 0.75-1.05; P=0.15). Baseline TFPI levels and nAPCsr did not modify the effect of postmenopausal hormone therapy on ischemic stroke. Treatment-induced mean changes of -28% in free TFPI and +65% in nAPCsr did not change the risk of ischemic stroke (interaction P=0.452 and 0.971, respectively). In subgroup analyses, baseline nAPCsr was inversely associated with lacunar strokes (OR per SD increase, 0.74; 95% CI, 0.57-0.96; P=0.025) and baseline free TFPI interacted with treatment to increase large vessel atherosclerotic strokes (P=0.008). CONCLUSIONS: Procoagulant changes in TFPI or nAPCsr do not modify the increased ischemic stroke risk due to postmenopausal hormone therapy. Clinical Trial Registration- URL: www.clinicaltrials.gov. Unique identifier: NCT 00000611.
Authors: Sylvia Wassertheil-Smoller; Susan L Hendrix; Marian Limacher; Gerardo Heiss; Charles Kooperberg; Alison Baird; Theodore Kotchen; J David Curb; Henry Black; Jacques E Rossouw; Aaron Aragaki; Monika Safford; Evan Stein; Somchai Laowattana; W Jerry Mysiw Journal: JAMA Date: 2003-05-28 Impact factor: 56.272
Authors: Charles Kooperberg; Mary Cushman; Judith Hsia; Jennifer G Robinson; Aaron K Aragaki; John K Lynch; Alison E Baird; Karen C Johnson; Lewis H Kuller; Shirley A A Beresford; Beatriz Rodriguez Journal: PLoS Clin Trials Date: 2007-06-15
Authors: Laura B Harrington; Marc Blondon; Mary Cushman; Andrew M Kaunitz; Jacques E Rossouw; Matthew A Allison; Lisa W Martin; Karen C Johnson; Jan Rosing; Nancy F Woods; Andrea Z LaCroix; Susan R Heckbert; Barbara McKnight; Nicholas L Smith Journal: Menopause Date: 2017-04 Impact factor: 2.953
Authors: Karen C Johnson; Aaron K Aragaki; Rebecca Jackson; Alex Reiner; Per Morten Sandset; Jan Rosing; Anders E A Dahm; Frits Rosendaal; JoAnn E Manson; Lisa W Martin; Simin Liu; Lewis H Kuller; Mary Cushman; Jacques E Rossouw Journal: Arterioscler Thromb Vasc Biol Date: 2015-12-17 Impact factor: 8.311